Vyndaqel(Tafamidis Meglumine)

Vyndaqel is a transthyretin stabilizer used for the treatment of the heart disease (cardiomyopathy) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients to decrease the cardiovascular mortality and cardiovascular-related hospitalization.

Recommended Dosage: The recommended dosage of Vyndaqel is 80 mg (4 × 20 mg tafamidis meglumine capsules) orally once daily. Swallow the capsules whole and not crush or cut. This medicine may be taken with or without food. 

If puking occurs after dosing, and the intact Vyndaqel capsule is noticed, then an additional dose of Vyndaqel capsule should be administered if possible. If no capsule is noticed, then no additional dose of Vyndaqel is needed, with resumption of dosing the very next day as usual.

• The vyndaqel capsule should be added to the standard of care to treat patients with ATTR-PN. Health specialists should evaluate patients and continue to assess the requirement for other therapy, including the requirement for liver transplantation, as part of this standard of care.
• As there are no evidence exist regarding the use of tafamidis meglumine capsules post-liver transplantation, use of tafamidis meglumine should be stopped in those who undergo liver transplantation.
• The medicine vyndaqel 20 mg contains no more than 44mg sorbitol in each capsule. Sorbitol is a source of fructose. The additive effect of concomitantly used products containing sorbitol and dietary intake of sorbitol should be taken into account. The content of sorbitol in medicine for oral use may affect the bioavailability of other medicines for oral use administered concomitantly.
• Findings suggest that Vyndaqel treatment may cause fetal harm if administered to a pregnant woman. Pregnancy planning as well as prevention should be considered for females of reproductive age/potential.
• Available findings/data have shown excretion of tafamidis in human milk. A risk to the newborns or infants cannot be excluded. It is not advisable to use tafamidis meglumine during breast-feeding.
• Depending on the pharmacokinetic as well as pharmacodynamic profile, tafamidis meglumine is believed to have no or negligible influence on the potential to drive or operate machines. 

What documents are required to import VYNDAQEL to India?

VYNDAQEL (Tafamidis Meglumine) Capsules can be imported by patients or government hospitals on the name of the patients only. 

The following documentation are required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Proof of Identity (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is VYNDAQEL available in India?

VYNDAQEL (tafamidis meglumine capsule) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the basis of Named Patient Supply (NPS). Indian Pharma Network (IPN) is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

VYNDAQEL can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of VYNDAQEL (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for vyndaqel price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the VYNDAQEL (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.